Secondary Logo

Journal Logo

April 15th, 2015 - Volume 68 - Issue 5
pp: 487-608,e69-e87

Reduced Immune Activation During Tenofovir–Emtricitabine Therapy in HIV-Negative Individuals

Castillo-Mancilla, Jose R.; Meditz, Amie; Wilson, Cara; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(5):495-501, April 15th, 2015.

Effect of Hormonal Contraception on the Function of Plasmacytoid Dendritic Cells and Distribution of Immune Cell Populations in the Female Reproductive Tract

Michel, Katherine G.; Huijbregts, Richard P. H.; Gleason, Jonathan L.; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(5):511-518, April 15th, 2015.


Baseline Antiretroviral Resistance Mutations and Treatment-Emergent Resistance in HIV-1 RNA-Suppressed Patients Switching to EVG/COBI/FTC/TDF or Continuing on Their PI-, NNRTI-, or RAL-Based Regimen

Andreatta, Kristen; Kulkarni, Rima; Abram, Michael E.; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(5):519-526, April 15th, 2015.

Risk Factors and Mortality Associated With Resistance to First-Line Antiretroviral Therapy: Multicentric Cross-sectional and Longitudinal Analyses

Pinoges, Loretxu; Schramm, Birgit; Poulet, Elisabeth; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(5):527-535, April 15th, 2015.

Changes in HIV RNA and CD4 Cell Count After Acute HCV Infection in Chronically HIV-Infected Individuals

Gras, Luuk; de Wolf, Frank; Smit, Colette; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(5):536-542, April 15th, 2015.

Sofosbuvir for Chronic Hepatitis C Virus Infection Genotype 1–4 in Patients Coinfected With HIV

Rodriguez-Torres, Maribel; Gaggar, Anuj; Shen, Gong; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(5):543-549, April 15th, 2015.

Implementation and Operational Research: Integrated Pre-Antiretroviral Therapy Screening and Treatment for Tuberculosis and Cryptococcal Antigenemia

Pac, Lincoln; Horwitz, Mara Murray; Namutebi, Anne Marion; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(5):e69-e76, April 15th, 2015.


Expanding Substance Use Treatment Options for HIV Prevention With Buprenorphine–Naloxone: HIV Prevention Trials Network 058

Metzger, David S.; Donnell, Deborah; Celentano, David D.; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(5):554-561, April 15th, 2015.

Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor–Based Combination Antiretroviral Therapy: The D: A: D Study

Bruyand, Mathias; Ryom, Lene; Shepherd, Leah; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(5):568-577, April 15th, 2015.

The Science of Being a Study Participant: FEM-PrEP Participants' Explanations for Overreporting Adherence to the Study Pills and for the Whereabouts of Unused Pills

Corneli, Amy L.; McKenna, Kevin; Perry, Brian; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(5):578-584, April 15th, 2015.

Brief Report: Validation of a Quantitative HIV Risk Prediction Tool Using a National HIV Testing Cohort

Haukoos, Jason S.; Hopkins, Emily; Bucossi, Meggan M.; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(5):599-603, April 15th, 2015.

Implementation and Operational Research: The Impact of Option B+ on the Antenatal PMTCT Cascade in Lilongwe, Malawi

Kim, Maria H.; Ahmed, Saeed; Hosseinipour, Mina C.; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(5):e77-e83, April 15th, 2015.


Outcomes From Treating Tuberculosis With Rifampicin or Rifabutin in HIV-Infected Persons Also Receiving Antiretroviral Therapy

Rawson, Timothy M.; Brima, Nataliya; Almajid, Fahad; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(5):e84-e87, April 15th, 2015.


Show: